Patients with type 2 diabetes mellitus are at the higher risk of development of on arteriosclerosis based cardiovascular
diseases. Epidemiological studies have shown that diabetic dislipidemiawith hypertriglyceridemia, presence of small
dense LDL subfraction, low concentration of HDL-cholesterol and increased postprandial lipemia can represent
a serious threat. Several studies have found significant decrease of cardiovascular morbidity and mortality after
a treatment of diabetic dislipidemia, namely by statins and fibrates. Contemporary therapeutic algorhithms of
European and American professional societies for the hyperlipidemia treatment classify diabetes mellitus as an
equivalent of already developed complication of atherosclerosis. Our article presents pathophysiology of the diabetic
dislipidemia, recommended target values of pasma lipids in diabetic patients and an overview of present possibilities
of pharmacotherapy of the diabetic dislipidemia.
diabetic dislipidemia, cardiovascular diseases, statins, fibrates, combination therapy of hypolipidemia,
polyenic fatty acids.